the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs — CTC-TCM-FZ

Non-small Cell Lung Cancer(NSCLC) Clinical Trial

Official title:
A Study on the"Fuzheng"Therapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation

Status Completed

Clinical Trial Summary

Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis. The investigators' study will elaborate the clinical significance of CTCs intervented by Traditional Chinese Medicine(TCM) in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.

Clinical Trial Description

Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells play a key role in the process of distant metastasis.In recent years, research results have shown that CTCs may become a emerging marker and new target in the treatment of lung cancer. The investigators' study will elaborate the clinical significance of CTCs intervented by TCM in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer. ;

Study Design

Related Conditions & MeSH terms

Lung Neoplasms
Non-small Cell Lung Cancer(NSCLC)

Clinical Trial Details

NCT number	NCT02603003
Study type	Interventional
Source	Shanghai University of Traditional Chinese Medicine
Contact
Status	Completed
Phase	Phase 1
Start date	June 2015
Completion date	September 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01712217` - A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib	Phase 1/Phase 2
Not yet recruiting	`NCT06332755` - Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors	Phase 1
Recruiting	`NCT02820116` - The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation	Phase 2
Active, not recruiting	`NCT02667743` - Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC	Phase 3
Recruiting	`NCT02036359` - Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca	Phase 2
Not yet recruiting	`NCT05765877` - Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT01637597` - Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation	N/A
Completed	`NCT05169801` - To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC	Phase 3